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Background: Although the role of oral propranolol in treating IH is now well-recognized worldwide, the variation of treatment eﬀec-
tiveness over time and patients adherence have not been documented among Saudi.
Objective: To identify the variation of eﬀectiveness over the treatment period and the adherence to treatment of oral propranolol
among Saudi children treated for infantile hemangiomas (IH).
Patients and methods: Children presented for treatment of problematic IH between February 2012 and September 2015 were recruited
in a prospective observational study of oral propranolol at 2 mg/kg/day. Data about patients’ adherence (categorized based compliance
with the scheduled visits and treatment administration), lesion comparative response score (based on the relative improvement compared
to previous visit) and possible side-eﬀects were collected during follow-up. Treatment was stopped once the lesions failed to show sig-
niﬁcant improvement. Serial digital photography was used for response and ﬁnal outcome assessments.
Results: Thirty-six cases were enrolled at a median (range) age of 6 (2–55) months. Cases were classiﬁed as 19 minor and 17 major,
including 10 with ulcerations. Adherence was poor in 12 (33.3%), moderate in 4 (11.1%) and good in 19 (52.8%). Excluding the poorly
adherent, the mean duration of treatment and follow up were 6 ± 3.4 and 7 ± 4.6 months, respectively. A mean comparative response
score of 1.67 from a maximum of 2 was achieved during the ﬁrst month of treatment, then gradually diminished reaching 0.19 and 0 at 8
and 10 months respectively. Patients who successfully completed 6 months of treatment (n = 19) were more likely to present with major
lesions (68.4% vs. 33.3%, P = 0.047) and at an earlier median age (4 vs. 11 months, P = 0.018). Complete or near complete responses was
47% achieved. All ulcerated lesions healed at a median of 2 (1–4) months.
Conclusion: The most dramatic response to treatment appeared during the ﬁrst month, then progressively diminished toward negli-
gible beneﬁts beyond 8 months. Adherence to treatment can pose a challenge to achieving satisfactory outcomes.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Infantile hemangiomas (IHs) are very common benign
vascular tumors present early in life in about 5–10% of
infants and characterized by a period of rapid growth fol-
lowed by gradual involution (Drolet et al., 1999; Frieden
et al., 1997). Despite its major drawbacks in children, oral
steroid has been the main eﬀective treatment for problem-
atic hemangiomas (Bennett et al., 2001) until the ﬁrst
observations made by Leaute-Labreze et al. (2008) of theehalf of King Saud University.
ommons.org/licenses/by-nc-nd/4.0/).
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tion, since it has largely replaced all other treatment modal-
ities to become the treatment of choice (Drolet et al., 2013).
The eﬀectiveness and safety of propranolol has been
well-demonstrated in many retrospective (Marqueling
et al., 2013) and prospective studies (Janmohamed et al.,
2015; Chang et al., 2015), including many randomized tri-
als (Leaute-Labreze et al., 2013, 2015; Hogeling et al.,
2011). However, the variability of its eﬀectiveness over
the treatment period and the optimal treatment duration
have not been described among a Saudi population. More-
over, Saudi patients’ adherence to the treatment regime,
which is known to be problematic among children with
chronic illnesses, has yet to be addressed.
Here we performed an observational prospective
outpatient-based study to document the relative eﬀective-
ness of a propranolol protocol for treating children with
IH, focusing mainly on describing the patterns of lesion
response over time and patients’ adherence.
2. Patients and methods
2.1. Patients
All patients referred to our clinic at King Saud Univer-
sity Medical City with problematic IH between February
2012 and September 2015 were enrolled in a prospective
study to assess the eﬀectiveness, response pattern, side-
eﬀects and compliance of our propranolol treatment pro-
gram. The study is approved by our local IRB at King
Saud University College of Medicine (project number E-
15-1737). The eligible patients were all children younger
than 8 years-old, who presented with problematic IH caus-
ing disﬁgurement, ulceration, pain or compression to
nearby structures. The exclusion criteria were; children
younger than one month of age, previous propranolol ther-
apy, history of congenital heart diseases and PHACE syn-
drome or signiﬁcant respiratory illnesses requiring
continuous medication use. Due to the accumulated evi-
dence on the safety of propranolol for treating IH, our pre-
treatment screening was limited to a pediatrician referral
for general exam, assessment of blood pressure, heart rate,
blood sugar and performing an electrocardiogram.
2.2. Treatment
In our protocol, the propranolol total targeted dose
(TTD) was 2 mg/kg/day divided into two equal doses.
Patients were instructed to start at 70% of the TTD and
to add 10% of the TTD every two days, until reaching
100% within a week. During the subsequent visits, the
doses were adjusted as the child gained weight. Care givers
were instructed to report a list of possible side-eﬀect symp-
toms, including: changes in feeding, sleeping and bowel
movement patterns, change in activities and worsening res-
piratory symptoms. The ﬁrst visit was scheduled at two
weeks after treatment and was limited to treatment toler-ance and initial compliance assessment. The ﬁrst treatment
response evaluation visit was scheduled at 1 month after
starting treatment, with subsequent visits scheduled every
2 months.
To assess the ideal treatment duration and its long-term
eﬀectiveness, we did not specify a treatment period, how-
ever, care givers were informed that they have the choice
to stop treatment after 6 months if the lesion is stabilized
without progressive improvement over any subsequent
two-month treatment interval.
2.3. Classification and response assessment
To assess treatment response, sequential digital pho-
tographs were taken during each visit and stored in each
patient’s electronic database. To date, there is no universal
consensus on the ideal IH severity and activity scoring sys-
tem, as most published literatures describe various endoge-
nously developed scoring schemes. Generally, most
hemangioma activity evaluation scoring systems are based
on the size, depth, color and ulceration, (Janmohamed
et al., 2015; Schneider et al., 2014) while in assessing the
lesion severity additional factors are considered to indicate
higher severity, such as facial location, compression and
associated pain (Haggstrom et al., 2012).
We have adopted a simpliﬁed hybrid scoring system
based on the above cited criteria. The lesions were simply
classiﬁed into major or minor, where major lesions include:
any facial lesion >2.5 cm, body lesions >5 cm, as well as
ulcerating, painful, markedly raised (>3 cm) lesions or
lesions causing compression to adjacent structures. Final
response was recoded at the last visit for patients who com-
pleted at least 6 months of follow-up and was based on the
deﬁnition of complete or near complete resolution
described by Leaute-Labreze et al. (2015). A simpliﬁed
comparative sequential response scoring is adopted by
comparing the change in color, size and ulcer status of each
visit photo in relation to the previous visit (Fig. 1). Because
of the natural tendency of hemangioma to improve sponta-
neously, a scale of zero was assigned if there was either a
minimal or no change.
The sequential responses scoring and ﬁnal outcome were
based on the average evaluation of three independent
physicians who are experienced in treating skin lesions.
Each was separately asked to view the patient’s serial pho-
tographs and record their assessment based on our scoring
system. An example of the sequential response scoring
scheme is shown in Figs. 2 and 3.
Patients’ adherence to propranolol treatment was
assessed at each follow up visit based on two elements;
adherence to the scheduled clinical visits and parents com-
mitment to administer the recommended propranolol
doses. It was categorized into three major categories; good
adherence (those who took the recommended dose and
followed-up for at least 6 months), moderate (those who
decided to stop treatment or lost follow-up after 2 months)
and poor (for the remaining cases).
Figure 1. The box display our comparative scoring system. The bar graph shows the comparative sequential response over 10 months, each bar represent
the average patients’ IH response compared to the previous visit.*, Only 12 patients continued treatment after 8 months.
Figure 2. Photographs shows examples of our comparative scoring system at the ﬁrst and second month.
Figure 3. Photograph shows example of our comparative scoring system at 4, 6, 8 and 10 months intervals. Slight improvements are still scored as 0.
A. Al-Jazaeri / Journal of Dermatology & Dermatologic Surgery 21 (2017) 1–6 3
4 A. Al-Jazaeri / Journal of Dermatology & Dermatologic Surgery 21 (2017) 1–62.4. Statistical methods
Mann–Whitney test was used to compare medians,
while the Fisher-Exact test was used for comparing cate-
gorical variables. A P-value of <0.05 was considered statis-
tically signiﬁcant.3. Results
3.1. Patients and compliance
Thirty-six patients (20 girls and 16 boys) were enrolled
in our study with a median (range) age at presentation of
6 (2–55) months. Four were excluded, 3 had lesions that
did not require treatments and the parent of the other child
declined propranolol treatment. Most of the lesions were
located in the face (54%), while the remaining lesions were
distributed as shown in Table 1. Two patients had multiple
lesions. Twenty-two (61.1%) lesions were slightly elevated,
7 (19.4%) were markedly elevated and the other 7 were sig-
niﬁcantly elevated. The severity classiﬁcation at presenta-
tion was distributed into 19 major and 17 minor lesions,
with 10 having ulcerative surfaces.
Of the 36 enrolled patients, 12 (33.3%) demonstrated
poor adherence as they did not follow-up after their ﬁrst
clinical visit. Four (11.1%) cases had moderate adherence
and the remaining 19 (52.8%) had good adherence. For
patients who started treatment, the mean duration of treat-
ment and follow-up were 6 ± 3.4 and 7 ± 4.6 months
respectively. Twenty-four (66.7%) of the patients com-
pleted at least 1 month of treatment and 19 (52.8%) com-
pleted 6 months. None of the care givers reported any
diﬃculties in administering the propranolol preparation
as it was well-accepted by all children. Of the 19 patients
who have completed at least 6 months of follow-up, 7
(36.8%) stopped their treatment at a mean duration of 9
± 2.1 months because of a lack of perceived response since
the previous visit. Factors that might impact the likelihood
of compliance are displayed in Table 2. Compared to
patients with minor lesions, patients with major lesions
were more likely to continue to follow-up at 6 months
(68.43% vs. 35.3%, P = 0.047). Age at presentation also
played an important role in determining the likelihood of
long-term but not short-term follow-up. Patients who
followed-up for 6 months are likely to have been presented
at an earlier median age compared to those who have notTable 1
Lesions’ distribution.
Location Lesions (n = 36)
Face 20
Neck 5
Limbs 3
Buttock 5
Oral 3
Chest 1(Table 2). Other factors, such as gender and ulcerating
lesions, did not impact the likelihood of follow-up at either
1 or 6 months.
3.2. Treatment response pattern
As expected, the initial response to oral propranolol
during the ﬁrst month was remarkable in all patients, with
16 (47.1%) showing the maximum response score of 2 and
all remaining showed slight improvement. Of the 10
patients presented with ulcerating lesions, 8 continue to
follow-up and all had their ulcer healed at a median (range)
of 2 (1–4) months. However, as time passes the compara-
tive eﬃcacy of propranolol diminishes to reach the mini-
mum at 10 months, at which none of the treated patients
showed a noticeable response (Fig. 1). It is worth noting
that, due diminishing response, only 12 patients opted to
continue taking their propranolol at this point. Finally,
of the 19 patients that completed more than 6 months of
treatment, 9 (47%) had achieved complete or near complete
responses.
The treatment was well-tolerated and there were no
major complications recorded. After the ﬁrst month of
treatment, 4 (16.7%) of the 24 patients reported minor
problems. Two reported minor sleeping disturbances and
another patient had trivial feeding diﬃculties, all resolved
during subsequent visits. The third reported a slight
increase of seasonal bronchiolitis marked by coughing
and wheezing that improved spontaneously without cessa-
tion of propranolol.
4. Discussion
The general clinical outcomes of propranolol treatment
of IH is consistent with what has been previously published
in terms of safety and eﬃcacy (Tan et al., 2015; Ma et al.,
2013; Menezes et al., 2011). However, this study described
the patterns of patients’ adherence and response in order to
oﬀer a better understanding of patients interaction during
propranolol treatment.
Patients/care giver adherence is a major however, fre-
quently overlooked component of evaluating any treat-
ment eﬀectiveness. Non-adherence to medication or
treatment plan among patients with chronic illnesses is a
primary cause of treatment failure in children (WHO,
2003). Only around 50% of children comply with their pre-
scribed treatment (Matsui, 1997), particularly those with
chronic illnesses such as asthma (Gibson et al., 1995;
Celano et al., 1998; Bender and Bender, 2005). Moreover,
a systematic review of medication adherence among chil-
dren with sickle cell disease revealed a wide variability in
adherence, ranged from 16% to 89% (Walsh et al., 2014).
In recent randomized trial by Leaute-Labreze et al.
(2015), the number of patients who failed to continue their
assigned treatment after the initial randomization varied
from 65.5% in the placebo group to 36% in the 3 mg/kg/-
day group. Similarly, Ma et al. (2013) reported a round
Table 2
Factors that might have inﬂuenced the patients’ compliance at 1 and 6 months of follow-up. NS; diﬀerence was not statistically signiﬁcant, * diﬀerence was
statistically signiﬁcant.
Follow up At 1 month (n = 24) At 6 months (n = 19)
Girls/boys 13/11, NS 11/8, NS
Ulcerating (yes/no) 8/16, NS 6/13, NS
Severity (major/minor) 15/9, NS 13/6, P = 0.047*
Age at presentation (median)
Successful follow up vs. Dropout 5 (2–55) months vs. NS 12.5 (2–42) months 4 (2–18) months vs. P = 0.018* 11 (2–55) months
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had a 33% overall dropout after the initial clinical visit,
which seems to concentrate among patients with minor
lesions and those presented at older age, although the dif-
ference in treatment dropout did not reach a signiﬁcant
level until the sixth month of follow-up. This can be
explained by the diﬀerence in perceived symptom severity,
which has been shown to positively inﬂuence patients’ com-
pliance in adult and pediatric populations (Sappok et al.,
2001; Lagi et al., 2006; Jones et al., 2015). The observed
decline in compliance among the older age group is proba-
bly related to the patient selection process or selection bias,
as care givers who sought care at an earlier age of their chil-
dren are likely to be keener on treatment. Whereas, decline
in compliance is less likely to be related to the lack of eﬀec-
tiveness with advanced children’s age, as propranolol is
persistently eﬀective beyond the proliferative stage (Vivas-
Colmenares et al., 2015; Zvulunov et al., 2011). Another
noticeable observation is the gradual fading of patients’
adherence to propranolol with time, as demonstrated by
around 33% cessation of treatment after the 6 months
interval. We attribute this, to a larger extent, to the dimin-
ishing IH response to propranolol with time that might
have negatively inﬂuenced the care givers’ perceived treat-
ment eﬀectiveness, which is a well-known factor that
impacts patients’ compliance (Hammami et al., 2004;
Williams et al., 2007) in addition to the duration of treat-
ment, which can be an independent factor in declining
treatment adherence, as noted for other treatment proto-
cols (Pakistan Multicentre Amoxycillin Short Course
Therapy (MASCOT) Pneumonia Study Group, 2002).
Medication palatability, which is also known to play a role
in children treatment adherence (Dagan et al., 1994;
Wandstrat and Kaplan, 1997), has not been an issue in
our sugar-based propranolol formulation.
To improve compliance, physicians should focus on
improving the parent-physician relationship by spending
more time explaining the treatment protocol, the impor-
tance of compliance and answering their concerns (Spath,
2000). Doctor availability and easy access to care can also
enhance parents’ engagement with their treatment plan
(Liptak, 1996).
The pattern of response reported here shows that the
most dramatic response occurs during the ﬁrst two months
of treatment initiation, which is in line with the ﬁndings of
previous studies (Hogeling et al., 2011; Ma et al., 2013).
Although most physicians tend to set the propranolol treat-ment duration to 6 months, this has largely been based on
previous observation, rather than documented evidence
(Leaute-Labreze et al., 2015; Hogeling et al., 2011). In
our longitudinal study, we were able to document the pat-
tern of improvement, which was highest immediately after
treatment initiation, then dropped steeply after the
4 months point. Although improvement continued after
this point, it was at a much smaller scale. No further
improvements were noticeable beyond 8 months. Conse-
quently, we propose a propranolol treatment duration of
6 months with an option extension up to 8 months in cases
where eﬀectiveness is still noticeable. We believe that exten-
sion of treatment beyond 8 months is unlikely to oﬀer sig-
niﬁcant beneﬁts in lieu of the natural involution tendency
of IH.
5. Conclusion
Saudi children treated with propranolol for IH share the
similar response described previously by others. However,
adherence to treatment during the ﬁrst 8 months plays a
major role in the overall eﬀectiveness and outcome and
should be an integral component in any treatment proto-
col. Compliance can be enhanced by greater eﬀorts toward
engaging the care givers during initial visits and by stress-
ing the safety and eﬀectiveness of the treatment. Sharing
the expected response pattern with care givers is a valuable
tool that could further enhance compliance and improve
the overall treatment satisfaction.
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